Malignant glioma: Who benefits from adjuvant chemotherapy? Journal Article


Authors: DeAngelis, L. M.; Burger, P. C.; Green, S. B.; Cairncross, J. G.
Article Title: Malignant glioma: Who benefits from adjuvant chemotherapy?
Abstract: We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.
Keywords: adult; cancer survival; aged; middle aged; survival analysis; major clinical study; cancer adjuvant therapy; chemotherapy, adjuvant; combined modality therapy; glioma; brain neoplasms; prospective studies; cancer mortality; carmustine; randomized controlled trials; glioblastoma; antineoplastic agents, alkylating; oligodendroglioma; nitrosourea derivative; humans; prognosis; human; priority journal; article
Journal Title: Annals of Neurology
Volume: 44
Issue: 4
ISSN: 0364-5134
Publisher: Wiley Blackwell  
Date Published: 1998-10-01
Start Page: 691
End Page: 695
Language: English
DOI: 10.1002/ana.410440418
PUBMED: 9778271
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 12 December 2016 -- Source: Scopus
Altmetric Score
MSK Authors